Medidata Experts Present New Insights on Risk-Based Quality Management, Decentralized Clinical Trials, and Real World Data at SCOPE Summit

• Medidata to be joined by panelists from Moderna, Bayer, Parexel, and Circuit Clinical
• Medidata has long been a leader at the SCOPE Summit, with exhibits and presentations highlighting innovative technology solutions for clinical trial operations
• SCOPE Participant Engagement Awards, co-created by Kelly McKee, Medidata vice president, Decentralized Clinical Trials, to recognize achievements in improving access, awareness, and participation in clinical trials

NEW YORK–(BUSINESS WIRE)–Medidata, a Dassault Systèmes company, will be leading multiple sessions at the upcoming Summit for Clinical Ops Executives (SCOPE) on trial diversity, risk based quality management (RBQM), decentralized clinical trials (DCT), real world data, sensors and wearables, and randomization and trial supply management (RTSM). Medidata is a top signature sponsor of the event held February 6-9.

“We are passionate about patient-focused, data-driven clinical operations, from study feasibility, to financial management to risk based quality management,” said Fareed Melhem, senior vice president Medidata AI. “SCOPE is an important event for sharing and exchanging information about advancements in the industry, and we are excited for all the new and improved enhancements to our clinical operations offering coming in 2023.”

Medidata’s presence at SCOPE includes showcasing technology that improves connectivity across the trial lifecycle, leverages historical data and analytics to promote diversity and inclusion in clinical trials, and operationalizes the new generation of decentralized clinical trials.

SCOPE 2023 Presentations: In addition to the featured presentations below, Medidata will also be moderating several breakout tracks, and chairing the clinical supply and med device trials tracks.

Driving Faster and More Representative Trials: The Key Data Needed to Accelerate Timelines While Meeting Diversity Goals – Jef Benbanaste, vice president of product, Intelligent Trials

Reinventing the Six Minute Walk Test: A Novel Approach to Digital Measures – Melissa Ceruolo, senior director, Biomarker Analytics

Great Expectations: Harnessing Historical Insights to Accelerate RBQM Strategies – Olgica Klindworth, senior director, R&D, Medidata RBQM, with Moderna

DCT Fireside Chat with Industry Leaders – Kelly McKee, vice president, Decentralized Clinical Trials, Medidata, with Bayer

Partnering for Success, a Modern Solution to Outsourcing – David Geismar, senior vice president, Professional Services, Medidata, with Moderna Therapeutics

Benefits of Using Separate Inventory Management Systems when Combined with IRT/RTSM – Marc Kaufman, director – RTSM Customer Adoption and Value Realization, Medidata

The Truth Behind the Financial Impact of Decentralized Clinical Trials – Meghan Harrington, vice president Clinical Trial Financial Management, Medidata, with Parexel and Circuit Clinical

Learn more about Medidata’s presence at SCOPE 2023 and engage with Medidata on its event page for the latest updates.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 2,000+ customers and partners access the world’s most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 2,000+ customers and partners access the world’s most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

Contacts

Tom Paolella

Senior Director, Corporate Communications & Affairs

+1-848-203-7596

[email protected]

Paul Oestreicher

External Communications Director

+1-917-522-4692

[email protected]